Stocks and Investing
Stocks and Investing
Thu, December 6, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, December 5, 2018
[ 12:00 AM ] - WOPRAI
Tue, December 4, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Charles Duncan Upgraded (VNDA) to Buy and Held Target at $43 on, Dec 4th, 2018
Charles Duncan of Cantor Fitzgerald, Upgraded "Vanda Pharmaceuticals Inc." (VNDA) to Buy and Held Target at $43 on, Dec 4th, 2018.
Charles has made no other calls on VNDA in the last 4 months.
There are 3 other peers that have a rating on VNDA. Out of the 3 peers that are also analyzing VNDA, 0 agree with Charles's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Charles
- Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $26 on, Thursday, November 8th, 2018
- Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $31 on, Tuesday, October 16th, 2018
- Derek Archila of "Oppenheimer" Maintained at Buy with Increased Target to $29 on, Friday, September 21st, 2018